Melanoma drugs carry serious side effects; oncologists need better toxicity data

A new systematic review identifies major safety concerns with checkpoint inhibitors and targeted therapies used to treat melanoma, but reveals a troubling gap in how these toxicities are tracked and reported. For pharmaceutical companies, health systems, and regulators, the finding underscores an urgent need for standardized safety monitoring to help clinicians manage these powerful drugs more effectively.

Originaltitel: Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review